Mexiprim ampoules 0.05/ml 5ml №5

Dosage Form

solution for intravenous and intramuscular administration.

Description

Colorless or slightly yellowish transparent liquid.

Pharmacotherapeutic group

Antioxidant agent.

Pharmacological properties. Pharmacodynamics

Mexiprim^® refers to heteroaromatic antioxidants. It has a wide range of pharmacological activity: increases the body's resistance to stress, exhibits an anxiolytic effect, which is not accompanied by drowsiness and muscle relaxant effect; possesses nootropic properties, prevents and reduces the disorders of learning and memory that occur during aging and exposure to various pathogenic factors; has an anticonvulsant effect; shows antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol.

The drug improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes membrane structures of blood cells (erythrocytes and platelets). It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.

The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxidase, increases the ratio of lipid-protein, reduces the viscosity of the membrane, increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to preserving the structurally functional organization of biomembranes, and using the organomers, and using the organomers, and using the organomers, and using the organomers, and using the organomers, the body, the body, the body, and the body, in addition to the bodywork, the body, the body, and the body, in addition to the bodywork, the body, and the body, in addition to the organomers, etc. Mexiprim increases the content of dopamine in the brain. It causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

Pharmacological properties. Pharmacokinetics

The maximum plasma concentration of Mexiprim ranges from 50 to 100 ng / ml.

The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively. Mexiprim is extensively metabolized in the human body to form its glucuron-conjugated product. On average, 12 hours in the urine excreted 0.3% of the unchanged drug and 50% in the form of glucuron conjugate from the administered dose. Mexiprim and its glucuron conjugate are most intensely excreted during the first 4 hours after taking the drug. The urinary excretion rates of Mexiprim and its conjugated metabolite have significant individual variability.

Indications for use

·         Acute disorders of cerebral circulation (as part of complex therapy);

·         Encephalopathy;

·         Vegetative dystonia;

·         Anxiety states in neurotic and neurosis-like states;

·         Mild cognitive disorders of various genesis (psychoorganic and asthenic syndromes, consequences of traumatic brain injuries, atherosclerosis, senile and atrophic processes, neuroinfection and intoxication);

·         Memory disorders and intellectual impairment in the elderly;

·         The impact of extreme (stress) factors;

·         Abstinence syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

·         Acute intoxication with antipsychotic drugs.

Contraindications

Acute hepatic and / or renal failure, increased individual sensitivity to the drug. Children's age, pregnancy, breastfeeding - due to insufficient knowledge of the drug in these categories of patients.

Dosage and administration

Mexiprim^® administered intramuscularly or intravenously (struino or drip). Doses are selected individually. When the infusion method of administration of the drug should be diluted in physiological sodium chloride solution. Begin treatment with a dose. 50-100 mg 1-3 times a day, gradually increasing the dose to obtain a therapeutic effect. Jet Mexiprim^® injected slowly over 5-7 minutes drip - with speed 40-60 drops per minute. The maximum daily dose does not exceed 800 mg.

In acute disorders of cerebral circulation Mexiprim^® used in complex therapy in the first 2-4 days intravenously, 200-300 mg once a day, then intramuscularly 100 mg 3 times a day. The duration of treatment is 10-14 days.

With dyscirculatory encephalopathy in the decompensation phase of Mexiprim^® should be administered intravenously in a stream or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly 100 mg 2-3 times a day for the next 2 weeks. For course prophylaxis of dyscirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days.

For mild cognitive impairment in elderly patients and for anxiety disorders, the drug is used intramuscularly in a daily dose of 100-300 mg per day for 14-30 days.

With alcohol withdrawal syndrome, Mexiprim is administered in a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days.

In acute intoxication with antipsychotics, the drug is administered intravenously at a dose of 50-300 mg per day for 7-14 days.

Side effect

Rarely - nausea, dryness of the oral mucosa, drowsiness, allergic reactions.

Overdosage

Symptoms: sleep disturbance (insomnia, in some cases - drowsiness).

Treatment: as a rule, it is not required - the symptoms disappear on their own within 24 hours.

In severe cases of insomnia, it is recommended to take sleeping pills.

Interaction with other drugs

Mexiprim is compatible with psychotropic drugs; enhances the action of benzodiazepine anxiolytics, anti-parkinsonian drugs and Carbamazepine. Reduces the toxic effect of ethyl alcohol.

Special notes

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor reactions.

Release form

Solution for intravenous and intramuscular administration of 50 mg / ml.

By production at FSUE “Moscow Endocrine Plant”, Russia

On 2 ml or 5 ml in ampoules of neutral glass of the NS-3 brand or import.

On 5 ampoules in a blister strip packaging from a film of polyvinyl chloride and aluminum foil.

On 1, 2 or 3 blister packs with instructions for medical use of the drug, ampoule with a knife or scarifier are placed in a pack of cardboard.

For hospitals in 6, 12, 20, 50 or 100 blister packs with foil with 3, 6, 10, 25 or 50 instructions for medical use of the drug, knives or scarificatory ampoules are placed in a cardboard box or in boxes of corrugated cardboard. When packing ampoules with notches, rings or break points, scarificators or ampoule knives are not inserted.

By production at LLC NTFF Polisan, Russia

On 2 ml or 5 ml in ampoules of neutral glass of the NS-3 brand or import, or ampoules of brown glass.

On 5 ampoules in a blister strip packaging from a film of polyvinyl chloride, or from a film of polyvinyl chloride and aluminum foil, or a film of polyvinyl chloride and a film cover. On 1, 2 or 3 blister packs with instructions for medical use of the drug, ampoule with a knife or scarifier are placed in a pack of cardboard.

For hospitals, 6, 12, 20, 50 or 100 blister packs with foil or coating film, respectively, with 6, 12, 20, 50 or 100 instructions for medical use of the drug, ampoule knives or scarifiers are placed in a cardboard box or in boxes corrugated cardboard. When packing ampoules with notches, rings or break points, scarificators or ampoule knives are not inserted.

Storage conditions

In the dark place at a temperature of no higher than 20 ° C. Keep out of the reach of children.

Shelf life

Do not use after the expiration date printed on the package.